(Reuters) - French drugmaker Genfit SA said on Thursday it will begin a late stage trial later this year of its lead treatment for a liver-destroying condition, saying it failed a midstage trial in ...
Morning Overview on MSN
Gut-liver serotonin pathway found to limit nanoparticle and viral delivery
Scientists at the University of Science and Technology of China have identified a signaling chain that starts with gut bacteria, triggers serotonin release from intestinal cells, and ends with liver ...
Background Metabolic-associated steatotic liver disease (MASLD) is a prevalent chronic liver disease affecting approximately ...
Sensitivity of Circulating Tumor DNA for Detection of Minimal Residual Disease Recurrence or Relapse in Patients With Melanoma A retrospective study at Memorial Sloan Kettering Cancer Center ...
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results